Trial Profile
Phase I, single-center, non-randomized study of nifedipine GITS/candesartan fixed-dose combination in patients with hepatic impairment
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 02 Jan 2017
Price :
$35
*
At a glance
- Drugs Candesartan cilexetil/nifedipine (Primary)
- Indications Essential hypertension
- Focus Adverse reactions; Pharmacokinetics
- 02 Jan 2017 New trial record
- 27 Dec 2016 Results published in the International Journal of Clinical Pharmacology and Therapeutics